Skip to content
  • Home
  • Visit our other Journals
    • VJHemOnc
    • VJOncology
    • VJNeurology
    • VJRegenmed
    • VJHemOnc-E
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjneurology logo
VJDementia
Logo
  • Diseases
    Alzheimer's Disease
    Dementia
    Dementia with Lewy Bodies
    Frontotemporal Dementia
    Vascular Dementia
    Mild Cognitive Impairment
    View all Diseases
  • Topics
    Diagnostics
    Biology
    Biomarkers
    Treatment
    Clinical Care
    Prevention
    View all Topics
  • Conferences
    AAIC 2023
    BNA 2023
    AD/PD 2023
    ARUK 2023
    CTAD 2022
    AAIC 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Frontotemporal Dementia

The promise of tau aggregation inhibitors in dementia 2:04
The promise of tau aggregation inhibitors in dementia
Sonya Miller • 17 Jul 2023
Investigating TDP-43 pathology with cryptic exons 1:37
Investigating TDP-43 pathology with cryptic exons
Matthew Keuss • 17 Mar 2023
TDP-43 aggregation drives loss of UNC13A, a risk gene for ALS & FTD 3:27
TDP-43 aggregation drives loss of UNC13A, a risk gene for ALS & FTD
Matthew Keuss • 17 Mar 2023
de novo proteins generated from cryptic exon translation in ALS & FTD 1:27
de novo proteins generated from cryptic exon translation in ALS & FTD
Matthew Keuss • 17 Mar 2023
Targeting cellular senescence in tauopathies 2:20
Targeting cellular senescence in tauopathies
Rakez Kayed • 17 Aug 2022
Next steps in dementia biomarkers 1:26
Next steps in dementia biomarkers
Marc Suárez-Calvet • 26 Jul 2022
Anti-HMGB1 agents for the treatment of Alzheimer’s disease 1:57
Anti-HMGB1 agents for the treatment of Alzheimer’s disease
Rakez Kayed • 17 Aug 2022
Tau fibrils versus tau oligomers in neurotoxicity and neurodegeneration 4:45
Tau fibrils versus tau oligomers in neurotoxicity and neurodegeneration
Rakez Kayed • 17 Aug 2022
Tau oligomers trigger astrocyte senescence in tauopathy models 3:14
Tau oligomers trigger astrocyte senescence in tauopathy models
Rakez Kayed • 17 Aug 2022
Biomarkers for frontotemporal dementia 3:53
Biomarkers for frontotemporal dementia
Julio Rojas-Martinez • 4 Apr 2022
Plasma NfL as a biomarker for frontotemporal dementia 1:21
Plasma NfL as a biomarker for frontotemporal dementia
Julio Rojas-Martinez • 4 Apr 2022
Diagnostic tools for neurodegenerative disease 1:14
Diagnostic tools for neurodegenerative disease
Davide Tampellini • 18 Mar 2022
Dipeptide repeat proteins and the NLRP3 inflammasome in FTD 0:57
Dipeptide repeat proteins and the NLRP3 inflammasome in FTD
Sarah Ryan • 1 Mar 2022
Next steps for research into the NLRP3 inflammasome in dementia 1:19
Next steps for research into the NLRP3 inflammasome in dementia
Sarah Ryan • 1 Mar 2022
Understanding tau proteostasis using iPSC 3:36
Understanding tau proteostasis using iPSC
Selina Wray • 29 Mar 2021
The role of phosphorylated tau in clinical trials 2:02
The role of phosphorylated tau in clinical trials
Elisabeth Thijssen • 4 Aug 2020
  • 1
  • 2
  • Next
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJDementia via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJDementia logo
The content of VJDementia is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy